Home » Covid, the EMA evaluates the anti-arthritis treatment in serious patients: the outcome in mid-October

Covid, the EMA evaluates the anti-arthritis treatment in serious patients: the outcome in mid-October

by admin

Tocilizumab was one of the first drugs to be considered against Sars-CoV-2 disease (beraking latest news Salute) – Tocilizumab was one of the first drugs to be considered at the start of the pandemic as a potential treatment for Covid-19, for via “its ability to block the action of interleukin-6, a substance produced by the immune system in response to inflammation”, an element that “plays an important role in Covid-19 disease”.

Even in Italy this path was already attempted in March 2020 (the first Covid cases treated off label in Naples) and a large study to evaluate the drug had been launched shortly. Now the EMA will consider whether to authorize the extension of use of this anti-arthritis drug authorized for the first time in the EU in 2009.

The CHMP opinion, together with any requirements for further studies and safety monitoring, will be forwarded – the EMA recalls in a note – to the European Commission, which will issue a final legally binding decision applicable in all EU member states.

below) // the var will be used by PaywallMeter to target the event on the correct pixel settings_testata.fbq_swg_promo = ‘3250029561771476’; fbq (‘init’, ‘3250029561771476’); fbq (‘track’, ‘PageView’);

See also  Thanks Basaglia. by Pier Aldo Rovatti. – Mental Health Forum

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy